For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Neurocrine Biosciences, Inc.

Calculating rank

USPTO Granted Patents = 123

% Expired Patents = 11.4

CIPO Patents = 5

EPO Patents = 30

Trademarks = 39

Forward Citations = 717

Loading Chart...

Loading Chart...

136 inventors (with patents filed for the assignee):

Chen Chen (23 out of 34 patents)

Zhiqiang Guo (22 out of 25 patents)

Neil Ashweek (19 out of 24 patents)

4. Martin W Rowbottom (19 out of 41 patents)

5. Yun-Fei Zhu (18 out of 18 patents)

6. Warren Stanfield Wade (16 out of 32 patents)

7. Charles Q Huang (14 out of 19 patents)

8. James R McCarthy (12 out of 79 patents)

9. Dongpei Wu (11 out of 18 patents)

10. Timothy Richard Coon (11 out of 26 patents)

11. Christopher F O'Brien (11 out of 12 patents)

12. Graham Beaton (10 out of 11 patents)

13. Fabio C Tucci (10 out of 20 patents)

14. Donald Nicholas Hettinger (10 out of 10 patents)

15. Nicole Harriott (9 out of 14 patents)

Core Competencies:

VMAT2 Inhibitors

CRF Receptor Antagonists

Pharmaceutical Formulations

Endometriosis Treatment

Gonadotropin-Releasing Hormone

Congenital Adrenal Hyperplasia

Synthetic Methods

Pyridoisoquinolines

Triazoles

Monoamine Re-Uptake Inhibitors

Sleep Inducing Compounds

Polymorphs

123 patents: Sort by Forward Citations

1. 12686680 - Substituted pyrazolo[1,5-α]pyrimidines as CRF receptor antagonists (2026-07-21),

2. 12649741 - Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors (2026-06-09),

3. 12582634 - Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine (2026-03-24),

4. 12486250 - Muscarinic receptor 4 antagonists and methods of use (2025-12-02),

5. 12421193 - GPR52 modulators and methods of use (2025-09-23),

6. 12383536 - CRF receptor antagonists and methods of use (2025-08-12),

7. 12128033 - Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine (2024-10-29),

8. 12102637 - Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis (2024-10-01),

9. 12083227 - Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis (2024-09-10),

10. 11730739 - Treatment of congenital adrenal hyperplasia (2023-08-22),

11. 11718618 - Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors (2023-08-08),

12. 11713324 - Gonadotropin-releasing hormone receptor antagonists and methods relating thereto (2023-08-01),

13. 11654142 - Methods for the administration of certain VMAT2 inhibitors (2023-05-23),

14. 11459305 - Processes for the preparation of uracil derivatives (2022-10-04),

15. 11439629 - Methods for the administration of certain VMAT2 inhibitors (2022-09-13),

Company Overview

Neurocrine Biosciences, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing innovative treatments for neurological and endocrine disorders. The company specializes in pharmaceutical formulations, particularly in the areas of VMAT2 inhibitors and CRF receptor antagonists. Its research encompasses critical therapeutic areas such as endometriosis, congenital adrenal hyperplasia, and the modulation of gonadotropin-releasing hormone, utilizing advanced synthetic methods and compounds like pyridoisoquinolines.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

123 Patents

#47 in San Diego, CA

#715 in California

#3,162 in US

#6,515 in the World

San Diego, CA, United States of America

Neurocrine Biosciences, Inc.

Forward Citations = 717

136 inventors:

Chen Chen (23 out of 34 patents)

Zhiqiang Guo (22 out of 25 patents)

Neil Ashweek (19 out of 24 patents)

4. Martin W Rowbottom (19 out of 41 patents)

5. Yun-Fei Zhu (18 out of 18 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Neurocrine Biosciences, Inc.. Retrieved from https://idiyas.com/company/neurocrine-biosciences

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…